Issue 188

Shortwave Life Sciences psilocybin drug shows positive results in anorexia trial

Shortwave Life Sciences has announced it has achieved a significant breakthrough in its ambitions to transform eating disorder care with positive pre-clinical results from its latest pharmacodynamics study, demonstrating the safety of its psilocybin-based drug combination for the treatment of anorexia nervosa.

“This is a monumental step forward for Shortwave. Our relentless pursuit of breakthrough mental health treatments comes with the responsibility of ensuring safety at every stage,” commented Shortwave Life Sciences CEO Rivki Stern Youdkevich.

“We are proud of the positive outcomes from this rigorous pre-clinical trial, further validating our patent-pending drug combination and buccal delivery system.

“With this success, we are reaffirmed in our approach to addressing the global mental health crisis.”

READ MORE

UK’S FIRST TRADE ASSOCIATION FOR PSYCHEDELICS LAUNCHES

The UK’s first trade association for psychedelics – Psychedelic Industry UK (PsyIndyUK) – has launched to represent the UK’s growing psychedelic medicine sector.

PsyIndUK has launched to encourage collaboration and knowledge sharing across the psychedelics industry, as well as representing the sector with policymakers and regulators.

The collaboration aims to develop new therapeutics for trauma-related mental health disorders, including post-traumatic stress disorder (PTSD).

Read More

MILLIONS COULD BENEFIT FROM PSILOCYBIN THERAPY, SHOWS STUDY

Up to 62% of patients currently receiving treatment for depression in the US could qualify for psilocybin therapy if approved.

“Our findings suggest that if the FDA gives the green light, psilocybin-assisted therapy has the potential to help millions of Americans who suffer from depression,” said lead author Syed Fayzan Rab.

“This underscores the importance of understanding the practical realities of rolling out this novel treatment on a large scale.”

Read More

SCIENCE AND RESEARCH

A study has been published that explores large-scale brain connectivity changes following the administration of LSD, d-amphetamine, and MDMA.

The Centre for Psychedelics Health and Research has launched at Providence Care Hospital in partnership with Queens University Faculty of Health Sciences.

A review article has looked at psychedelics and schizophrenia, outlining possible therapeutic strategies to pave the way to future clinical trials.

Psy Post reports that a new study has shown that spiritual transformations may help sustain the long-term benefits of psychedelic experiences.

REGULATION AND LEGISLATION

Pink Sheet reports that the European Commission has registered a European citizens’ initiative that explains how the EU can foster innovative psychedelic-assisted treatments.

The Center for State Policy Analysis at Tufts University has evaluated a Massachusetts ballot question that would legalise certain psychedelics for therapeutic and personal use.

BUSINESS AND INVESTMENT

Virgin founder Richard Branson has expressed his interest in psychedelics as new mental health treatments, encouraging an end to the War on Drugs.

Clearmind Medicine has announced the notice of an International Patent Application for its Ibogaine Combination Therapy.

Awakn Life Sciences has announced the upsizing and closing of its private placement financing, upsizing from up to $1,000,000 to up to $2,000,000.

Enosis CEO, Prash Puspanathan, and co-founder and CEO of Psylo, Josh Ismin, discuss how they are using tech to tackle medicinal psychedelics.

ARTICLES OF INTEREST

Pain News Network reports that the U.S. Food and Drug Administration is shutting down a pain management programme that helped supply fentanyl medication to patients suffering from severe cancer pain.

The World Health Organization has released a statement saying that a renewed focus on health – including mental health – is critical as Ukraine approaches its third winter amid full-scale war.

Partner with us